19-382 - Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung CancerStatus: open
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Treatment for Lung Cancer
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at firstname.lastname@example.org.
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
SponsorsThis trial is sponsored by ECOG-ACRIN.
Providers Associated With This Trial
- Daniel G. Cameron, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
- Brian E. Persing, M.D.Medical Oncologist and HematologistDivision Director, Medical Oncology; Arlene and Mayer Mitchell Chair of Medical Oncology; Program Director, Medical Oncology Fellowship; Assistant Professor of Medical Oncology